.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Farmers Insurance
Deloitte
Federal Trade Commission
Express Scripts
US Army
Mallinckrodt
Covington
Moodys

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,351,414

« Back to Dashboard

Which drugs does patent 7,351,414 protect, and when does it expire?


Patent 7,351,414 protects FORTEO and is included in one NDA. There has been one Paragraph IV challenge on Forteo.

This patent has fifty-six patent family members in thirty-four countries.

Summary for Patent: 7,351,414

Title:Method of reducing the risk of bone fracture
Abstract:The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracture, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fractur and/or reduce the incidence of non-vertebral fracture.
Inventor(s): Gaich; Gregory A. (Indianapolis, IN), Dere; Willard H. (Westlake Village Ventura, CA), Hock; Janet M. (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:11/684,996
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
LillyFORTEOteriparatide recombinant humanINJECTABLE;SUBCUTANEOUS021318-002Jun 25, 2008RXYesYes► Subscribe► SubscribeMETHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE► Subscribe
LillyFORTEOteriparatide recombinant humanINJECTABLE;SUBCUTANEOUS021318-002Jun 25, 2008RXYesYes► Subscribe► SubscribeMETHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED► Subscribe
LillyFORTEOteriparatide recombinant humanINJECTABLE;SUBCUTANEOUS021318-001Nov 26, 2002DISCNNoNo► Subscribe► SubscribeTREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,351,414

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,977,077 Method of increasing bone toughness and stiffness and reducing fractures► Subscribe
7,163,684Method of increasing bone toughness and stiffness and reducing fractures► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,351,414

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland343595► Subscribe
Peru10892000► Subscribe
New Zealand507056► Subscribe
Norway20072983► Subscribe
Norway323984► Subscribe
Norway20005947► Subscribe
Malaysia129227► Subscribe
South Korea100454207► Subscribe
Japan2017190332► Subscribe
Japan2015028065► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Julphar
Healthtrust
Federal Trade Commission
Accenture
Chinese Patent Office
UBS
Mallinckrodt
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot